Plain-English translation of NCT07369830 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether Clostridium butyricum (live) tablets, a type of beneficial live bacteria, can help restore normal bowel function in patients who have had surgery for very low rectal cancer. After this type of surgery, doctors temporarily create an opening (called an ileostomy) to allow waste to leave the body, then reverse it a few months later by reconnecting the intestines. The trial wants to see if taking this medication helps your gut bacteria recover and improves how your bowel works after that reconnection surgery.
After rectal cancer surgery with temporary ileostomy reversal, many patients struggle with bowel problems and reduced quality of life. Researchers believe that restoring healthy gut bacteria during recovery might improve these symptoms and help patients return to normal bowel function faster.
You likely qualify if…
You likely don't qualify if…
If you're accepted into this trial, you'll be randomly assigned to receive either a low dose of the medication (once per week), a high dose (twice per week), or no medication (standard care only). Starting one week after your ileostomy is created, you'll receive your assigned treatment through the opening in your intestine. Throughout the study — from before your surgery through 2 years after your intestines are reconnected — you'll provide stool samples and complete questionnaires about your bowel function and quality of life at scheduled visits (at 1 week, 2 weeks, 1 month, 3 months, 6 months, and beyond).
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China